Cellectar Biosciences, Inc. (CLRB)
- Previous Close
3.0600 - Open
3.0700 - Bid 3.0600 x 600
- Ask 3.1100 x 300
- Day's Range
2.9420 - 3.1000 - 52 Week Range
1.3300 - 4.4500 - Volume
492,010 - Avg. Volume
1,093,764 - Market Cap (intraday)
99.643M - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-3.1100 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.60
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
www.cellectar.comRecent News: CLRB
Performance Overview: CLRB
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLRB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLRB
Valuation Measures
Market Cap
98.72M
Enterprise Value
95.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.47
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-144.66%
Return on Equity (ttm)
-536.81%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-37.98M
Diluted EPS (ttm)
-3.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
9.56M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.44M